Thermo Fisher Scientific Inc. $TMO Shares Sold by Flossbach Von Storch SE

Key Points

• Flossbach Von Storch SE cut its stake in Thermo Fisher by 13.4%, selling 337,197 shares and leaving 2,178,901 shares (worth about $1.26 billion), which represents ~5.0% of the fund and is its 5th largest holding.
• Thermo Fisher beat Q1 estimates (EPS $5.44 vs. $5.25; revenue $11.01B, +6.2% YoY) and set FY2026 EPS guidance of 24.640–25.120, while analysts maintain a consensus "Buy" rating with an average target of $623.05.
• Insiders have sold shares recently (CEO Marc Casper sold 5,000 shares at $512.40) and insider ownership is low at 0.33%, while the company raised its quarterly dividend to $0.47 (annualized $1.88, ~0.4% yield).

Flossbach Von Storch SE trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 13.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,178,901 shares of the medical research company's stock after selling 337,197 shares during the quarter. Thermo Fisher Scientific makes up 5.0% of Flossbach Von Storch SE's holdings, making the stock its 5th largest holding. Flossbach Von Storch SE owned about 0.58% of Thermo Fisher Scientific worth $1,262,564,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of TMO. Wellington Management Group LLP raised its holdings in Thermo Fisher Scientific by 88.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock worth $1,309,292,000 after buying an additional 1,270,191 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Thermo Fisher Scientific by 54.7% in the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock worth $1,732,422,000 after buying an additional 1,262,967 shares during the period. Franklin Resources Inc. increased its position in shares of Thermo Fisher Scientific by 21.0% in the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock worth $2,874,069,000 after acquiring an additional 1,028,125 shares in the last quarter. Corient Private Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 89.1% during the second quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company's stock valued at $720,576,000 after acquiring an additional 825,649 shares during the period. Finally, Capital World Investors boosted its stake in Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. DZ Bank started coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They set a "buy" rating and a $610.00 target price on the stock. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. UBS Group reissued a "neutral" rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Finally, Barclays dropped their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a report on Tuesday, April 14th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $623.05.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares of the company's stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 0.3%

NYSE TMO opened at $468.21 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The firm's fifty day simple moving average is $498.38 and its 200-day simple moving average is $549.15. The company has a market capitalization of $174.00 billion, a PE ratio of 25.74, a price-to-earnings-growth ratio of 2.33 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analysts' expectations of $10.86 billion. During the same quarter last year, the firm earned $5.15 earnings per share. The business's revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 24.83 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were issued a $0.47 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.